Dementia with Lewy Bodies Consortium
The purpose of this study is to develop a collection of samples from individuals diagnosed with Lewy body dementia (DLB) or Lewy body dementia/MCI (mild cognitive impairment) who will be followed over a period of 5 years. The consortium will collect detailed clinical information, biospecimens, and imaging data. Led by top leaders in the field, this consortium will fill the gap in resources available for biomarker development in DLB and promote additional future research, including therapeutic trials, by having a readily available subject sample.
Requirements: Age 40-90 years of age; diagnosis of Lewy body dementia or Lewy body dementia/MCI; have at least 8 years of education, have a study partner. Subjects are required to undergo MRI scans, DaT SCAN imaging, lumbar punctures; clinical, laboratory, and cognitive testing; brain autopsy required.
The main objective of this study is to evaluate the effectiveness of a study drug called Neflamapimod on cognitive function in patients diagnosed with Dementia with Lewy Bodies. A study partner/caregiver is required.
For further information about this and other studies, please conact Aishwarya Niraula firstname.lastname@example.org or Tel: 858-246-3190.